Main content

    Melanoma Clinical Trials

    CPMC Cancer ServicesOpens new window | CPMC Center for Melanoma Research and TreatmentOpens new window


    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: A randomized Phase III, open label, multicenter, two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma
    Description: A study to compare the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma
    Investigator: David Minor, MD
    Eligibility: Subjects, 18 y/o and older, with histologically confirmed diagnosis of malignant melanoma
    Status: Coming soon
    Contact: Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study NEMO, MEK162A

    Title: A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
    Description: A Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
    Investigator: David Minor, MD
    Eligibility: Male and female subjects, 18 y/o and older, who have histologically confirmed cutaneous metastatic melanoma
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study GSK 117277

    Title: Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresectable, Stage IIIb-IV Melanoma
    Description: Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma
    Investigator: David Minor, MD
    Eligibility: Subjects, 18 y/o and older, with histologically confirmed diagnosis of malignant melanoma
    Status: Active and open to enrollment
    Contact: Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study Amgen 20110264

    Title: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection
    Description: A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection
    Investigator: David Minor, MD
    Eligibility: Male & female subjects, 18 y/o and older, with a completely resected histologically confirmed high-risk Stage IIIa, IIIb or IIIc cutaneous melanoma determined to be V600E/K mutation positive by a central laboratory
    Status: Acitve and open to enrollment
    Contact: Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study GSK 115532

    Title: Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
    Description: Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
    Investigator: David Minor, MD
    Eligibility: Subjects, 18 y/o and older, who have Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic)
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study GSK 115984

    Title: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk Melanoma
    Description: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
    Eligibility: Subjects, 18 y/o and older with surgically resected Melanoma stage iiiB, iiiC, IV M1a or IV M1b who have not begun any adjuvant treatement post-surgery
    Investigator: David Minor, MD
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study EGOG-E1609

    Title: A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
    Description: Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
    Investigator: David Minor, MD
    Eligibility: Subjects, 18 y/o and older, who have Diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma (AJCC Stage IIIC or IV)
    Status: Coming Soon
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study MEK162

    • updated April 2014

    Back to top